Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
Biological Collection and Registry of Patients Who Will Have a TAVR (Transcatheter Aortic Valve Replacement) Intervention

A sample of plasma and whole blood will be obtained at 4 time points (pre-procedural, early post-procedural, at hospital discharge and during an eventual visite at 3 or 6 months post-procedural). Test for platelet reactivity (LTA, light transmittance aggregometry and Elisa PRI, Platelet reactivity index), multimeric VWF (von Willebrand factor) …

aortic valve replacement
  • 1 views
  • 22 Jan, 2021
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over

The aim of the study is to compare, in real life, the risk benefit (including both major bleeding and thrombotic events (TE) and death from any cause) associated with direct oral anticoagulants (DOA) and with anti vitamin K (VKA) in older adults ( 80 years) suffering from non valvular atrial …

fibrillation
apixaban
rivaroxaban
dabigatran
vitamin k
  • 3 views
  • 23 Jan, 2021
  • 2 locations
Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)

The MAS Study is an observational, multicentre, prospective cohort study in Non valvular Atrial fibrillation (NVAF) patients treated with one of the direct oral anticoagulants (DOACs) available in Italy for NVAF patients. The general aim is to deepen the knowledge of DOAC treatment in NVAF patients, by measuring the plasma …

fibrillation
anticoagulants
anticoagulation therapy
  • 1 views
  • 23 Jan, 2021
  • 1 location
Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

Post-authorization observational, prospective, follow-up study of a cohort of patients with non-valvular atrial fibrillation who are treated with direct oral anticoagulants (DOACs) to evaluate the clinical course (occurrence of stroke, major bleeding and mortality) and its correlation with clinical, pharmacokinetic (plasma concentrations), pharmacodynamic (haemostatic) and pharmacogenetic factors.

fibrillation
edoxaban
apixaban
rivaroxaban
embolism
  • 17 views
  • 26 Jan, 2021
  • 6 locations
Novel Oral Anticoagulants in Stroke Patients

The present study will monitor and explore acute neurovascular emergencies in patients treated with NOACs compared to those under treatment with VKAs. The primary aims of this study are: (1) To investigate characteristics, management and outcome of intracranial hemorrhage (ICH) in patients treated with NOAC compared to VKA. (2) To …

stroke
intracranial hemorrhage
anticoagulants
  • 24 views
  • 24 Jan, 2021
  • 1 location
Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)

Aim of this study is to describe clinical and procedural characteristics of real-world population initiated on triple antithrombotic therapy (double antiplatelet therapy+anticoagulant) or double antithrombotic therapy (single antiplatelet therapy+anticoagulant) after percutaneous coronary intervention (PCI). Investigator's driven trial, retrospective (2015-2019), multicenter Italian registry. Baseline clinical characteristics as well as procedural details …

myocardial infarction
thrombolytic agent
anticoagulation therapy
thrombosis
thrombolytic
  • 1 views
  • 24 Jan, 2021
  • 1 location
Bariatric Surgery and Pharmacokinetics of Apixaban

study we investigate the pharmacokinetic effects of bariatric surgery on apixaban.

gastric bypass
gastrointestinal transit
bariatric surgery
gastrectomy
gastric ph
  • 23 views
  • 23 Jan, 2021
  • 1 location
Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study

The purpose of this study is to evaluate the safety and efficacy of apixaban for the prevention of thromboembolism in adult patients with congenital heart disease (CHD) and non-valvular atrial

thromboembolism
apixaban
arrhythmia
  • 2 views
  • 03 Feb, 2021
  • 8 locations
Monitoring of NOAC Therapy: Standardizing Reference Intervals

This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and rivaroxaban) in ethnic Chinese patients.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients

Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.

  • 39 views
  • 22 Feb, 2021
  • 2 locations